Page last updated: 2024-11-06

uk 68798

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID71329
CHEMBL ID473
CHEBI ID4681
SCHEMBL ID16135
MeSH IDM0175348

Synonyms (128)

Synonym
AC-385
bdbm50031720
(dofetilide) n-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide
n-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide)
n-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (uk-68798)
n-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide dofetilide
n-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide
HMS3393N14
AB00639976-08
n-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide
gtpl2604
uk-68798
xelide
uk 68798
uk 68,798
dofetilida
1-(4-methanesulfonamidophenoxy)-2-(n-(4-methanesulfonamidophenethyl)-n-methylamine)ethane
uk-68,798
1-mspmpe
dofetilida [inn-spanish]
dofetilidum
tikosyn
dofetilidum [inn-latin]
c19h27n3o5s2
methanesulfonamide, n-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-
beta-((p-methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide
CHEBI:4681 ,
n-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide
MLS001424185
C07751
115256-11-6
dofetilide ,
MLS000759442
smr000466333
DB00204
dofetilide (jan/usp/inn)
tikosyn (tn)
D00647
NCGC00164549-01
HMS2089F03
HMS2051N14
CHEMBL473 ,
n-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
n-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide
A803396
AKOS005259921
HMS3261G03
dtxsid5046433 ,
tox21_112178
cas-115256-11-6
dtxcid3026433
BCP9000619
uk68798
HMS2232H19
CCG-101037
dofetilide [usan:usp:inn:ban]
r4z9x1n2nd ,
hsdb 7927
unii-r4z9x1n2nd
BCP0726000009
FT-0631076
dofetilide [ema epar]
dofetilide [vandf]
dofetilide [usp-rs]
dofetilide [mart.]
.beta.-((p-methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide
dofetilide [mi]
dofetilide [inn]
dofetilide [orange book]
dofetilide [who-dd]
dofetilide [jan]
dofetilide [usan]
dofetilide [usp monograph]
S1658
HMS3370B18
IXTMWRCNAAVVAI-UHFFFAOYSA-N
1-(4-methanesulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino]ethane
1-(4-methansulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino]ethane
AB00639976-06
HY-B0232
MLS006010154
NC00287
SCHEMBL16135
tox21_112178_1
NCGC00164549-02
NCGC00261036-01
tox21_500351
HB1078
1-(4-methanesulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino] ethane
n-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide
AB00639976_09
n-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide
n-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide
J-003271
uk 68789
uk68789
SR-01000759368-4
sr-01000759368
dofetilide, united states pharmacopeia (usp) reference standard
HMS3655A17
dofetilide, >=98% (hplc)
MRF-0000317
HMS3715H20
SW197667-2
BCP04770
Q3712521
dofetilide (tikosyn)
1-(4-methanesulphonamidophenoxy)-2-(n-(4-methanesulphonamidophenethyl)-n-methylamino)ethane
BRD-K86887724-001-05-6
H11953
methanesulfonamide, n-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-
nsc-786034
nsc786034
n-[4-(2-{[2-(4-methanesulfonamidophenyl)ethyl](methyl)amino}ethoxy)phenyl]methanesulfonamide
EN300-19768191
BD164377
dofetilide- bio-x
n-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-methanesulfonamide
dofetilida (inn-spanish)
c01bd04
dofetilide (mart.)
dofetilide (usp monograph)
n-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide
dofetilide (usp-rs)
dofetilde
dofetilide (usan:usp:inn:ban)
dofetilidum (inn-latin)
1-(4-methanesulfonamidophenoxy)-2-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects."( The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
MacNeil, DJ, 1997
)
0.3
"Existing drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects."( Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
Droszcz, W; Graff, O; Kawecka-Jaszcz, K; Kozlowski, JW; Krzeminska-Pakula, M; Kulakowski, P; Malolepszy, J; Ruzyllo, W; Swiatecka, G; Szechinski, J; Tendera, M; Wnuk-Wojnar, AM, 2001
)
0.31
" Three patients taking propafenone had serious treatment-related adverse effects that required drug discontinuation."( Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
Droszcz, W; Graff, O; Kawecka-Jaszcz, K; Kozlowski, JW; Krzeminska-Pakula, M; Kulakowski, P; Malolepszy, J; Ruzyllo, W; Swiatecka, G; Szechinski, J; Tendera, M; Wnuk-Wojnar, AM, 2001
)
0.31
" Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome."( A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
Klein, GJ; Krahn, AD; Yee, R, 2001
)
0.31
" Both dofetilide and sotalol were well tolerated during the long term with no statistically significant difference in the adverse events."( A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
Biffi, M; Borggrefe, M; Boriani, G; Brachmann, J; Butrous, GS; Capucci, A; Kornacewicz-Jack, Z; Lubinski, A; Niederle, R; Wnuk-Wojnar, AM, 2001
)
0.31
" Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up."( Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007
)
0.34
"Dofetilide appears safe and effective in preventing AF in patients refractory to other AADs undergoing catheter ablation."( Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation.
Beardsall, M; Frost, L; Khaykin, Y; Oosthuizen, R; Sarak, B; Seabrook, C; Shamiss, Y; Tsang, B; Tunney, D; Verma, A; Wulffhart, Z, 2009
)
0.35
" Risk factors for adverse events (AEs), defined as any arrhythmia or electrocardiogram change requiring dose reduction or cessation, were identified."( Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015
)
0.42
"We conducted a retrospective chart review of a cohort of 1404 patients initially loaded on dofetilide for atrial fibrillation suppression at the Cleveland Clinic from 2008 to 2012 to evaluate the incidence and risk factors for in-hospital adverse events and the long-term safety of continued use."( Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
Abraham, JM; Bassiouny, M; Bhargava, M; Janiszewski, D; Lawrence, D; Lindsay, B; Militello, M; Nissen, SE; Poe, S; Saliba, WI; Tanaka-Esposito, C; Vekstein, C; Wilkoff, BL; Wolski, K, 2015
)
0.42
"Dofetilide loading has a low but finite risk of TdP and other adverse events that warrant the current Food and Drug Administration-mandated practice of inpatient monitoring during drug loading."( Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
Abraham, JM; Bassiouny, M; Bhargava, M; Janiszewski, D; Lawrence, D; Lindsay, B; Militello, M; Nissen, SE; Poe, S; Saliba, WI; Tanaka-Esposito, C; Vekstein, C; Wilkoff, BL; Wolski, K, 2015
)
0.42
" Dofetilide was found to be safe in patients after myocardial infarction and those with congestive heart failure and left ventricular systolic dysfunction (ejection fraction of less than 35%)."( Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
Shenasa, F; Shenasa, M, 2016
)
0.43
" This improvement could potentially translate into enhanced patient safety outcomes, such as prevention of adverse drug reactions and decreased hospitalizations."( Impact of a Pharmacy-Cardiology Collaborative Practice on Dofetilide Safety Monitoring.
Dietrich, NM; Franck, AJ; Kaufmann, MR; McKillop, M; Panna, M; Quffa, LH, 2017
)
0.46
" Monitoring adherence is important as other studies have shown that up to 93% of patients on amiodarone experience an adverse drug event leading to a potentially lethal event."( Frequency of Adverse Event Monitoring in Ambulatory Patients on Amiodarone or Dofetilide.
Dick, T; Negrelli, J; Olson, JL; Rickard, JP, 2018
)
0.48
"To determine whether patients prescribed amiodarone or dofetilide are being monitored according to package labeling and guideline recommendations for adverse events."( Frequency of Adverse Event Monitoring in Ambulatory Patients on Amiodarone or Dofetilide.
Dick, T; Negrelli, J; Olson, JL; Rickard, JP, 2018
)
0.48
" The secondary objective was to determine rates of adverse drug events."( Frequency of Adverse Event Monitoring in Ambulatory Patients on Amiodarone or Dofetilide.
Dick, T; Negrelli, J; Olson, JL; Rickard, JP, 2018
)
0.48
"Amiodarone adverse event monitoring was lower than dofetilide in this cohort."( Frequency of Adverse Event Monitoring in Ambulatory Patients on Amiodarone or Dofetilide.
Dick, T; Negrelli, J; Olson, JL; Rickard, JP, 2018
)
0.48
"A common but serious side effect of many drugs is torsades de pointes, a rhythm disorder that can have fatal consequences."( Predicting the cardiac toxicity of drugs using a novel multiscale exposure-response simulator.
Kuhl, E; Sahli Costabal, F; Yao, J, 2018
)
0.48
" Dofetilide's most concerning adverse effect is QT prolongation and polymorphic VT, but providers should be aware of other rare significant side effects."( Stroke or side effect? dofetilide associated facial paralysis after direct current cardioversion for atrial fibrillation.
Steckman, D; Zhang, L, 2019
)
0.51
"The purpose of this study was to evaluate whether rapid switching from amiodarone to dofetilide is safe in atrial fibrillation patients with an ICD."( Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator.
Atkins, D; Bommana, S; Carroll, H; Gopinathannair, R; Jeffrey, C; Lakkireddy, D; Natale, A; Newton, D; Nydegger, C; Sharma, SP; Turagam, M, 2019
)
0.51
" No other significant adverse events were noted during follow-up."( Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator.
Atkins, D; Bommana, S; Carroll, H; Gopinathannair, R; Jeffrey, C; Lakkireddy, D; Natale, A; Newton, D; Nydegger, C; Sharma, SP; Turagam, M, 2019
)
0.51
"Cardiovascular adverse effects in drug development are a major source of compound attrition."( An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
Gabrielsson, J; Jirstrand, M; Martel, E; Pairet, N; Scheuerer, S; Wallman, M, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic and pharmacodynamic properties of UK-68,798, a novel selective potential class III antiarrhythmic agent, were studied in 18 patients with coronary artery disease."( Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug.
Cobbe, SM; Rasmussen, HS; Sedgwick, M; Walker, D, 1991
)
0.28
" The QTc interval versus dofetilide plasma concentration was analyzed by use of pharmacokinetic and pharmacodynamic modeling techniques."( Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
Funck-Brentano, C; Ghadanfar, MM; Jaillon, P; Le Coz, F; Morell, T, 1995
)
0.29
" Pharmacokinetic parameters were determined from plasma and urinary dofetilide concentrations; prolongation of the QTc interval was determined from three-lead electrocardiograms."( Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide.
Abel, S; Brearley, CJ; Eve, MD; Nichols, DJ, 2000
)
0.31
" Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels."( Effect of dofetilide on the pharmacokinetics of digoxin.
Dalrymple, I; Kleinermans, D; Nichols, DJ, 2001
)
0.31
" Pharmacokinetic parameters following intermittent treatment showed no accumulation."( Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.
Allen, MJ; Newgreen, MW; Nichols, DJ; Oliver, SD, 2002
)
0.31
"A 3-compartment pharmacokinetic model with first-order absorption characterized the time course of dofetilide concentrations."( A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker, DM; Jonsson, EN; Kenna, LA; Leishman, D; Milligan, PA; Wallis, R, 2005
)
0.33
" This model may prove valuable for assessing the risk of QT prolongation in humans for other drugs that selectively block the hERG channel on the basis of in vitro assays and pharmacokinetic properties."( A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker, DM; Jonsson, EN; Kenna, LA; Leishman, D; Milligan, PA; Wallis, R, 2005
)
0.33
" The individual concentration-time course of dofetilide was linked to the QT(c) interval via an effect compartment and a pharmacodynamic E(max) model, to account for the observed hysteresis."( Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs.
Al-Saffar, A; Duker, G; Eklund, G; Forsberg, T; Gabrielsson, J; Nilsson, LB; Ollerstam, A; Persson, AH; Visser, SA; Wiklund, SJ,
)
0.13
" It was found to have an equilibrium half-life of 11+/-8 min."( Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs.
Al-Saffar, A; Duker, G; Eklund, G; Forsberg, T; Gabrielsson, J; Nilsson, LB; Ollerstam, A; Persson, AH; Visser, SA; Wiklund, SJ,
)
0.13
"We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques."( Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.
Aarons, L; Dokoumetzidis, A, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic data were generated together with the monitoring of cardiovascular changes in order to compare effects relative to human exposure."( The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys.
Barecki-Roach, M; Bass, AS; Friedrichs, GS; Haushalter, TM; Hayes, R; Pastino, G; Reynolds, DL, 2008
)
0.35
" Pharmacokinetic parameters were determined for each dose."( The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys.
Barecki-Roach, M; Bass, AS; Friedrichs, GS; Haushalter, TM; Hayes, R; Pastino, G; Reynolds, DL, 2008
)
0.35
" A population pharmacokinetic model was developed using NONMEM."( The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.
Jonsson, EN; Karlsson, MO; Lindbom, L; Marshall, S; McFadyen, L; Tunblad, K, 2008
)
0.35
"Pharmacokinetic models considering sex and renal function as covariates were implemented from data published in pharmacokinetic studies."( Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity.
Baroudi, S; Basset, M; Benito, S; Dayan, F; Koloskoff, K; Llopis-Lorente, J; Mora, MT; Romero, L; Saiz, J; Trenor, B, 2023
)
0.91
"This study presents a novel methodology that combines pharmacokinetic and electrophysiological models to incorporate the effects of sex and renal function into in silico drug simulations and highlights their impact on TdP-risk assessment."( Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity.
Baroudi, S; Basset, M; Benito, S; Dayan, F; Koloskoff, K; Llopis-Lorente, J; Mora, MT; Romero, L; Saiz, J; Trenor, B, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Class III antiarrhythmic drugs may interact with other drugs by two major processes: pharmacodynamic and pharmacokinetic interactions."( Potentially significant drug interactions of class III antiarrhythmic drugs.
DeBisschop, M; Lower, DL; Martin, LG; Yamreudeewong, W, 2003
)
0.32
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" The terminal plasma elimination half-life is approximately 9-10 h and systemic bioavailability in the region of 100%."( Dofetilide, a novel class III antiarrhythmic agent.
Allen, MJ; Blackburn, KJ; Butrous, GS; Dalrymple, HW; Rasmussen, HS, 1992
)
0.28
" Low metabolic clearance in man resulted in complete bioavailability following oral administration."( Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.
Rasmussen, HS; Smith, DA; Stopher, DA; Walker, DK, 1992
)
0.28
" Compound 5 was shown to have good oral bioavailability and a favorable hemodynamic profile to produce a 3-fold increase of the ventricular fibrillation threshold and to terminate ventricular fibrillation, restoring sinus rhythm in anesthetized dogs."( Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
Bagli, JF; Ellingboe, JW; Kitzen, JM; Moubarak, IF; Nguyen, TT; Parsons, RW; Spinelli, W; Von Engen, D; Winkley, MW, 1992
)
0.28
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Dofetilide is a well-absorbed drug, but showed a reduction in observed bioavailability when delivered from the Pulsincap formulations, particularly at more distal GI tract sites."( Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract.
Bakhshaee, M; Binns, JS; Blackshaw, EP; Frame, MW; Frier, M; Humphrey, MJ; Nichols, DJ; Perkins, AC; Stevens, HN; Welling, PG; Wicks, SR; Wilson, CG, 2002
)
0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A dosing regimen using a loading infusion of two thirds of the total dose over 15 min with the remainder given over the following 45 min in six patients produced stable plasma concentrations and lengthening in QTc during the maintenance infusion."( Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug.
Cobbe, SM; Rasmussen, HS; Sedgwick, M; Walker, D, 1991
)
0.28
" Agents were compared over dosage ranges that produced maximal increases in QTc interval and monophasic action potential duration (MAPD)."( Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G, 1993
)
0.29
" Dosing on gestational day (GD) 11 was associated with right-sided oblique cleft lip and short tail, while dosing on day 13 caused digital hypoplasia and/or amputation."( Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity.
Brown-Woodman, PD; Danielsson, BR; Snow, MD; Webster, WS, 1996
)
0.29
"10 for dose-response relationship."( Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
Christiansen, EH; Christiansen, N; Frost, L; Mortensen, PE; Platou, ES; Tingleff, J, 1997
)
0.3
" Approximately 80% of drug is excreted in urine, so dosing must be based on creatinine clearance."( Dofetilide, a new class III antiarrhythmic agent.
Hilleman, DE; Lenz, TL, 2000
)
0.31
" Ctrough had a linear dependence on dose for both the twice daily and three times daily dosing regimens."( The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing.
Allen, MJ; Nichols, DJ; Oliver, SD, 2000
)
0.31
"The pharmacokinetics and pharmacodynamics of dofetilide are predictable and based on a linear relationship for both twice daily and three times daily dosing regimens."( The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing.
Allen, MJ; Nichols, DJ; Oliver, SD, 2000
)
0.31
" Therefore, dosage must be carefully adjusted to the length of QTc interval, calculated creatinine clearance and the presence of heart failure or recent infarction."( Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
Brendorp, B; Køber, L; Torp-Pedersen, C, 2000
)
0.31
" In-hospital initiation and dosage adjustment based on QTc and Cl(Cr) are necessary to minimize a small but nonnegligible proarrhythmic risk."( Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
Berk, M; Billing, CB; Brodsky, MA; Feld, GK; Singh, S; Yellen, L; Zoble, RG, 2000
)
0.31
" The risk is dose-dependent and can be minimized by adjusting the dosage according to creatinine clearance and QT interval, by excluding patients with known risk factors for long QT syndrome and torsades de pointes, and by starting treatment in an inpatient monitored setting for the first 3 days."( Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
Saliba, WI, 2001
)
0.31
" This relatively small interactive effect occurred only while peak plasma drug concentrations were developing at 1 to 3 hours after dosing and is probably caused by the known effect of verapamil to increase hepatic and portal bloodflow."( Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic.
Cheng, SL; Johnson, BF; Venitz, J, 2001
)
0.31
"0 mg on days 1, 5, 10, 17, and 24 with identical placebo capsules administered at all other times to match the dosing pattern of the other groups."( Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.
Allen, MJ; Newgreen, MW; Nichols, DJ; Oliver, SD, 2002
)
0.31
" The combination of scintigraphic and pharmacokinetic analysis permits identification of the site of drug release from the dosage form and pharmacokinetic parameters to be studied in man in a non-invasive manner."( Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract.
Bakhshaee, M; Binns, JS; Blackshaw, EP; Frame, MW; Frier, M; Humphrey, MJ; Nichols, DJ; Perkins, AC; Stevens, HN; Welling, PG; Wicks, SR; Wilson, CG, 2002
)
0.31
" Dofetilide is effective and safe when an elaborate procedure for dosing is implemented."( Dofetilide: a new drug to control cardiac arrhythmia.
Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Torp-Petersen, C, 2003
)
0.32
"To determine how well dofetilide and Betapace AF (sotalol, approved solely for atrial fibrillation and atrial flutter), with their detailed dosing and monitoring guidelines for safety, were accepted into clinical practice during the 2 calendar years after their introduction."( New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
Kramer, JM; LaPointe, NM; Pamer, CA, 2003
)
0.32
" market suggests that drugs without a risk-management program or detailed dosing guidelines were more likely than dofetilide or Betapace AF to be selected for treatment of atrial fibrillation and atrial flutter."( New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
Kramer, JM; LaPointe, NM; Pamer, CA, 2003
)
0.32
"Dose-dependent torsades de pointes has been shown to occur with dofetilide (Tikosyn) and sotalol HCl (Betapace AF); thus, detailed dosing and monitoring recommendations to minimize this risk are included in the product labeling for both drugs."( Evaluation of the dofetilide risk-management program.
Allen LaPointe, NM; Califf, RM; Chen, A; DeLong, E; Hammill, B; Kramer, JM, 2003
)
0.32
"Better adherence to several dosing and monitoring recommendations in the dofetilide group may be caused by the presence of the risk-management program."( Evaluation of the dofetilide risk-management program.
Allen LaPointe, NM; Califf, RM; Chen, A; DeLong, E; Hammill, B; Kramer, JM, 2003
)
0.32
" Reductions in subsequent dosage occurred in 12 patients, 4 for QT prolongation."( Clinical experience with dofetilide in the treatment of patients with atrial fibrillation.
Branyas, NA; Fogel, RI; Freeland, S; Padanilam, BJ; Prystowsky, EN; Rardon, DP; Rippy, JS, 2003
)
0.32
" Preprinted order forms or procedural guidelines, as well as computer-assisted dosing programs, can be utilized to prevent inappropriate or miscalculated dosing of these agents, which potentially can cause life-threatening ventricular arrhythmias."( Initiation and monitoring of class III antiarrhythmic agents.
Freeland, S; Worthy, C; Zolnierz, M, 2003
)
0.32
"To determine the effectiveness and safety of dofetilide in clinical practice as well as to ascertain whether clinicians are following established dosing guidelines."( Phase IV trial evaluating the effectiveness and safety of dofetilide.
Crouch, MA; Guanzon, AV,
)
0.13
" A 12-lead electrocardiogram (ECG) was obtained at baseline, 3 hours, and 51 hours after dosing to correspond to the Tmax after oral ingestion."( An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
Coleman, CI; Guertin, D; Henyan, NN; Kluger, J; McBride, BF; Min, B; Silver, BB; White, CM, 2006
)
0.33
" This risk is minimized by dosage adjustment according to creatinine clearance and QT(c) interval, by selecting patients without known risk factors for torsades and by initiating treatment in a monitored hospital setting for the first 3 days."( Dofetilide: a new class III antiarrhythmic agent.
Roukoz, H; Saliba, W, 2007
)
0.34
"Eighty consecutive patients received D dosing per Cockroft-Gault adjustment for creatinine clearance and QTc intervals."( Acute conversion of persistent atrial fibrillation during dofetilide initiation.
Arshad, A; Aziz, E; Cotiga, D; Joshi, S; Koneru, JN; Steinberg, JS, 2007
)
0.34
" Medication was dosed and administered according to the manufacturer's guidelines."( Usefulness of dofetilide for the prevention of atrial tachyarrhythmias (atrial fibrillation or flutter) after coronary artery bypass grafting.
Burke, P; Khawaja, O; Machado, C; Sekulic, M; Serafimovski, N, 2008
)
0.35
" Torsades de Pointes developed in two patients despite careful dosing and monitoring of QT changes."( Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
Banchs, JE; Gonzalez, MD; Naccarelli, GV; Patel, PP; Penny-Peterson, ED; Samii, SM; Wolbrette, DL; Young, SK, 2008
)
0.35
"To report 2 cases of drug dosage calculation errors that occurred when the Modification of Diet in Renal Disease (MDRD) equation was used for initiating drug therapy with dofetilide in elderly patients with chronic kidney disease."( Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation.
Denetclaw, TH; Dowling, TC; Oshima, N, 2011
)
0.37
"The initial dosing of dofetilide is based on eCrCl as specified by the drug manufacturer."( Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation.
Denetclaw, TH; Dowling, TC; Oshima, N, 2011
)
0.37
" In responses to all three QT-lengthening compounds, RR, QT and QTc(F) lengthened similarly in a dose-response manner in both the failing and normal hearts."( Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts.
Hamlin, RL; Kijtawornrat, A; Sawangkoon, S, 2012
)
0.38
" In a separate experiment, dofetilide treatment of GD 13 rats was followed 2, 4, 12, or 24 hr with iv dosing with the hypoxia marker, pimonidazole (60 mg/kg)."( The teratogenic effect of dofetilide during rat limb development and association with drug-induced bradycardia and hypoxia in the embryo.
Ababneh, DH; Oakes, DJ; Power, CA; Ritchie, HE; Webster, WS, 2013
)
0.39
" The risk of dofetilide induced torsade de pointes (Tdp) is low when used with strict dosing criteria guided by renal function, QT interval and concomitant drug therapy."( Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
Goldbarg, S; Jaiswal, A,
)
0.13
"The dofetilide label recommends using actual body weight (ABW) to calculate the Cockcroft-Gault creatinine clearance (CrCl) for the determination of the initial dose; however, few studies have attempted to evaluate this dosing recommendation in overweight and obese patients."( Evaluation of initial dofetilide dosing recommendation based on actual body weight in overweight and obese patients.
Cao, DX; Dinh, J; Eng, L; Kohatsu, A; Le, A; Mei, K; Mok, I; Moreau, N; Shin, J, 2015
)
0.42
"Our study provides the evidence on the safety of the current dofetilide dosing recommendation in overweight and obese populations in clinical practice."( Evaluation of initial dofetilide dosing recommendation based on actual body weight in overweight and obese patients.
Cao, DX; Dinh, J; Eng, L; Kohatsu, A; Le, A; Mei, K; Mok, I; Moreau, N; Shin, J, 2015
)
0.42
" One way to verify whether these in vitro findings are replicated in vivo is by the use of ultrasound examination of dosed pregnant rats."( The Effect of Dofetilide on the Heart Rate of GD11 and GD13 Rat Embryos, in vivo, Using Ultrasound.
Hegedus, E; Hung, TT; Oakes, D; Ritchie, H; Sood, S; Webster, W, 2015
)
0.42
" Dosing with dofetilide on GD11 caused severe bradycardia (∼ 60% reduction) 2 hours after dosing with recovery after 24 h of >60% of LD but death and slow HR among the HD embryos."( The Effect of Dofetilide on the Heart Rate of GD11 and GD13 Rat Embryos, in vivo, Using Ultrasound.
Hegedus, E; Hung, TT; Oakes, D; Ritchie, H; Sood, S; Webster, W, 2015
)
0.42
" As a result, the Federal Drug Administration (FDA) mandated in-hospital dofetilide initiation and adherence to a common dosing protocol."( Practice variation in the re-initiation of dofetilide: An observational study.
Afzal, MR; Atkins, D; Christensen, K; Dendi, R; Di Biase, L; Hurwitz, J; Jeffrey, C; Lakkireddy, D; Lavu, M; Natale, A; Pillarisetti, J; Pimentel, R; Reddy, M; Turagam, MK; Vacek, J, 2017
)
0.46
" Of 138 patients admitted for dofetilide reloading for atrial arrhythmias, 102 were reloaded at a previously tolerated dose, 30 with a higher dose from a previously tolerated dose and 2 at a lower dose; prior dosage was unknown in 4 patients."( Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias.
Bhargava, M; Cho, JH; Chung, MK; Kyriakakis, R; Lindsay, BD; Militello, M; Moore, JC; Niebauer, MJ; Poe, SM; Saliba, WI; Tchou, PJ; Varma, N; Vekstein, C; Wazni, OM; Wilkoff, BL; Wolski, K; Youn, SJ, 2017
)
0.46
"Although no TdP occurred in patients admitted to reload dofetilide at the same dose as previously tolerated, dosage adjustments or discontinuation was frequent and support the need for hospitalization for dofetilide reloading."( Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias.
Bhargava, M; Cho, JH; Chung, MK; Kyriakakis, R; Lindsay, BD; Militello, M; Moore, JC; Niebauer, MJ; Poe, SM; Saliba, WI; Tchou, PJ; Varma, N; Vekstein, C; Wazni, OM; Wilkoff, BL; Wolski, K; Youn, SJ, 2017
)
0.46
"Dofetilide, ranolazine, and a combination of these were administered in 4 incremental dosing regimens to horses with acutely pacing-induced AF."( Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.
Buhl, R; Carstensen, H; Flethøj, M; Haugaard, MM; Hesselkilde, EZ; Jespersen, T; Kanters, JK; Kjær, L; Pehrson, S, 2018
)
0.48
"Compared with men, women have longer corrected QT (QTc) intervals, lower clearance of dofetilide, and higher rates of drug-induced torsades de pointes, but the dofetilide dosing algorithm is the same for men and women."( Dofetilide dose reductions and discontinuations in women compared with men.
Al-Khatib, SM; Allen LaPointe, NM; Bahnson, TD; Campbell, KB; Daubert, JP; Jackson, KP; Picini, JP; Pokorney, SD; Sheng, S; Thomas, KL; Thomas, L; Yen, DC, 2018
)
0.48
" Electrocardiograms throughout dosing were analyzed, and rates of dofetilide discontinuations and dose reductions were compared in unadjusted and adjusted analyses."( Dofetilide dose reductions and discontinuations in women compared with men.
Al-Khatib, SM; Allen LaPointe, NM; Bahnson, TD; Campbell, KB; Daubert, JP; Jackson, KP; Picini, JP; Pokorney, SD; Sheng, S; Thomas, KL; Thomas, L; Yen, DC, 2018
)
0.48
" Additional studies are needed to evaluate the optimal dosing algorithm of dofetilide in women."( Dofetilide dose reductions and discontinuations in women compared with men.
Al-Khatib, SM; Allen LaPointe, NM; Bahnson, TD; Campbell, KB; Daubert, JP; Jackson, KP; Picini, JP; Pokorney, SD; Sheng, S; Thomas, KL; Thomas, L; Yen, DC, 2018
)
0.48
" Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance."( A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
Hussain, S; Maraj, I; Naccarelli, GV; Wolbrette, DL, 2019
)
0.51
"Dofetilide is an antiarrhythmic drug with dosing based on the Cockcroft-Gault formula using total body weight (TBW)."( Dofetilide-Associated QT Prolongation: Total Body Weight Versus Adjusted or Ideal Body Weight for Dosing.
Cui, Z; Kaplan, AV; Maloney, RW; Sangha, RS; Wang, SY; Welch, TD, 2018
)
0.48
"Dofetilide is an effective antiarrhythmic medication for rhythm control in atrial fibrillation, but carries a significant risk of pro-arrhythmia and requires meticulous dosing and monitoring."( Noninvasive assessment of dofetilide plasma concentration using a deep learning (neural network) analysis of the surface electrocardiogram: A proof of concept study.
Ackerman, MJ; Asirvatham, SJ; Attia, ZI; Friedman, PA; Kapa, S; Noseworthy, PA; Sugrue, A, 2018
)
0.48
" We previously reported this variability in a study of four human ether-a-go-go-related gene (hERG) potassium channel-blocking drugs in which each subject underwent intensive pharmacokinetic and pharmacodynamic sampling such that subjects had 15 time-matched plasma drug concentration and electrocardiogram measurements throughout 24 hours after dosing in a phase I clinical research unit."( Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs.
Blinova, K; Daluwatte, C; Patel, D; Schocken, D; Strauss, DG; Vicente, J; Wu, JC, 2019
)
0.51
" Although a recommended dose management algorithm for dofetilide exists, there is a range of real-world approaches to dosing the medication."( Applications of machine learning in decision analysis for dose management for dofetilide.
Biswas, M; Chung, M; Levy, AE; Newton-Cheh, C; Noseworthy, PA; Rosenberg, MA; Tarakji, K; Weber, R, 2019
)
0.51
" These 8 clusters were then used to define patient states in a tabular reinforcement learning model trained on 80% of dosing decisions."( Applications of machine learning in decision analysis for dose management for dofetilide.
Biswas, M; Chung, M; Levy, AE; Newton-Cheh, C; Noseworthy, PA; Rosenberg, MA; Tarakji, K; Weber, R, 2019
)
0.51
" A reinforcement learning algorithm informed by unsupervised learning was able to predict dosing decisions with 96."( Applications of machine learning in decision analysis for dose management for dofetilide.
Biswas, M; Chung, M; Levy, AE; Newton-Cheh, C; Noseworthy, PA; Rosenberg, MA; Tarakji, K; Weber, R, 2019
)
0.51
" The objective of this study was to describe prescribing practices of sotalol and dofetilide and to compare safety outcomes between standard and nonstandard dosing strategies."( Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Knowles, D; Malloy, R; Ting, C, 2020
)
0.56
" Nonstandard dosing was associated with a greater incidence of QTc prolongation compared to standard dosing (57."( Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Knowles, D; Malloy, R; Ting, C, 2020
)
0.56
" An analysis of drug exposure-time and high-resolution response-time data of HR and mean arterial blood pressure was performed after acute oral dosing of ivabradine, sildenafil, dofetilide, and pimobendan in Han-Wistar rats."( An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
Gabrielsson, J; Jirstrand, M; Martel, E; Pairet, N; Scheuerer, S; Wallman, M, 2021
)
0.62
" Therapeutic as well as excess dosage of dofetilide can lead to TdP, which is usually controlled by decreasing the dose or terminating drug administration."( Refractory Torsades de Pointes Due to Dofetilide Overdose.
Bhopalwala, A; Bhopalwala, H; Crosby, J; Dewaswala, N; Ganti, SS; Kharawala, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
potassium channel blockerAn agent that inhibits cell membrane glycoproteins that are selectively permeable to potassium ions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency19.62650.002541.796015,848.9004AID1347395; AID1347398
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
AR proteinHomo sapiens (human)Potency16.10660.000221.22318,912.5098AID743040; AID743042; AID743054
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.49710.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency28.34280.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.12100.000214.376460.0339AID720691; AID720692; AID720719
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.19540.001530.607315,848.9004AID1224819; AID1224820; AID1224821
pregnane X nuclear receptorHomo sapiens (human)Potency11.22020.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.37800.000229.305416,493.5996AID743069
cytochrome P450 2D6Homo sapiens (human)Potency27.54040.00108.379861.1304AID1645840
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency11.88320.001723.839378.1014AID743083
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.01780.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)1,023.00000.02201.64228.9000AID1207644
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)43.35000.00032.63119.0000AID1207185; AID1207738
Bile salt export pumpHomo sapiens (human)IC50 (µMol)420.70000.11007.190310.0000AID1449628; AID1473738
Potassium voltage-gated channel subfamily E member 1Homo sapiens (human)IC50 (µMol)204.83900.12004.048010.0000AID1207366; AID1207398
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)IC50 (µMol)1,023.00000.00132.24956.9000AID1207644
Sodium channel protein type 1 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00232.82969.0000AID1207156
Sodium channel protein type 4 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00013.507510.0000AID1207156
Potassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)IC50 (µMol)204.83900.12004.048010.0000AID1207366; AID1207398
Sodium channel protein type 7 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.03603.73359.0000AID1207156
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)43.35000.00032.59559.0000AID1207185; AID1207738
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)2.45370.00091.901410.0000AID1207215; AID1207460; AID1207492; AID1207520; AID1320524; AID161281; AID161283; AID1652308; AID1739148; AID1743139; AID240820; AID243151; AID290942; AID392051; AID408340; AID420668; AID728454; AID77985; AID82355
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki0.00700.00211.840710.0000AID290939; AID290940
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)43.35000.00032.63119.0000AID1207185; AID1207738
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)317.04720.00032.25459.6000AID1207185; AID1207554; AID1207644; AID1207738
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)386.79620.00033.64849.2000AID1207156; AID1207306; AID1207338; AID49032
Sodium channel protein type 9 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00602.77499.0000AID1207156
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Sodium channel protein type 2 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00003.740110.0000AID1207156
Sodium channel protein type 3 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00532.80859.0000AID1207156
Sodium channel protein type 11 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.03004.36959.0000AID1207156
Sodium channel protein type 8 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00113.47059.0000AID1207156
Sodium channel protein type 10 subunit alphaHomo sapiens (human)IC50 (µMol)300.00000.00803.17529.0000AID1207156
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Activity0.01100.01104.70559.4000AID270499
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (227)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
epithelial cell maturationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
male gonad developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
vestibular nucleus developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
secretory granule organizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to acidic pHPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to light stimulusPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell action potential involved in contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of protein targeting to membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
sodium ion transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
adult walking behaviorSodium channel protein type 1 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potential propagationSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuromuscular process controlling postureSodium channel protein type 1 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 1 subunit alphaHomo sapiens (human)
establishment of localization in cellSodium channel protein type 1 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 1 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
muscle contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
regulation of skeletal muscle contraction by action potentialSodium channel protein type 4 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
gastrin-induced gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
glucose metabolic processPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
heart developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
rhythmic behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of blood pressurePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of heart ratePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
iodide transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
erythrocyte differentiationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intracellular chloride ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
response to insulinPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
social behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
corticosterone secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear morphogenesisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intestinal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
auditory receptor cell developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
stomach developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal sodium ion absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to epinephrine stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
adrenergic receptor signaling pathwayPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cochlea developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
non-motile cilium assemblyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
osmosensory signaling pathwaySodium channel protein type 7 subunit alphaHomo sapiens (human)
response to bacteriumSodium channel protein type 7 subunit alphaHomo sapiens (human)
cellular homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 7 subunit alphaHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
sodium ion transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuron apoptotic processSodium channel protein type 2 subunit alphaHomo sapiens (human)
memorySodium channel protein type 2 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 2 subunit alphaHomo sapiens (human)
dentate gyrus developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 2 subunit alphaHomo sapiens (human)
cellular response to hypoxiaSodium channel protein type 2 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 3 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 3 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
thigmotaxisSodium channel protein type 11 subunit alphaHomo sapiens (human)
acute inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
chronic inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonogenesisSodium channel protein type 11 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to heatSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to xenobiotic stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to high light intensitySodium channel protein type 11 subunit alphaHomo sapiens (human)
protein kinase A signalingSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to auditory stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to prostaglandin ESodium channel protein type 11 subunit alphaHomo sapiens (human)
thermosensory behaviorSodium channel protein type 11 subunit alphaHomo sapiens (human)
mast cell degranulationSodium channel protein type 11 subunit alphaHomo sapiens (human)
cell motilitySodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
reflexSodium channel protein type 11 subunit alphaHomo sapiens (human)
micturitionSodium channel protein type 11 subunit alphaHomo sapiens (human)
skeletal muscle organ developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
artery developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to acetic acid induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to formalin induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
cellular response to coldSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to nitric oxideSodium channel protein type 11 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
action potential initiationSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of itchSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcitonin gene-related peptide receptor signaling pathwaySodium channel protein type 11 subunit alphaHomo sapiens (human)
small intestine smooth muscle contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
peripheral nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 8 subunit alphaHomo sapiens (human)
optic nerve developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 8 subunit alphaHomo sapiens (human)
regulation of heart rateSodium channel protein type 10 subunit alphaHomo sapiens (human)
sensory perceptionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of monoatomic ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 10 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (72)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium channel regulator activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
telethonin bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein-containing complex bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 4 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein phosphatase 1 bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A catalytic subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A regulatory subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 7 subunit alphaHomo sapiens (human)
osmolarity-sensing monoatomic cation channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 2 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 8 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
ATP bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 10 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (67)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
Z discPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 1 subunit alphaHomo sapiens (human)
nuclear bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 1 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 1 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 4 subunit alphaHomo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
late endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transport vesiclePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmic vesicle membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuron projectionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ciliary basePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lumenal side of membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral part of cellPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
monoatomic ion channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membraneSodium channel protein type 7 subunit alphaHomo sapiens (human)
glial cell projectionSodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 7 subunit alphaHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 2 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 2 subunit alphaHomo sapiens (human)
axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 2 subunit alphaHomo sapiens (human)
paranode region of axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 2 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
sarcoplasmSodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 3 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 11 subunit alphaHomo sapiens (human)
axonal growth coneSodium channel protein type 11 subunit alphaHomo sapiens (human)
C-fiberSodium channel protein type 11 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 11 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 8 subunit alphaHomo sapiens (human)
cell junctionSodium channel protein type 8 subunit alphaHomo sapiens (human)
axonSodium channel protein type 8 subunit alphaHomo sapiens (human)
cytoplasmic vesicleSodium channel protein type 8 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 8 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
presynaptic active zone membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
parallel fiber to Purkinje cell synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
postsynaptic density membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 8 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
axonSodium channel protein type 10 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 10 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
clathrin complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (256)

Assay IDTitleYearJournalArticle
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID24978Extrapolated in vivo clearance was measured by N-demethylation using scalling factors (female rat)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID59268Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 0.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID78068Maximum rate of depolarization (MRD) during phase 0 in guinea pig right papillary muscle was determined at concentration 5 x 10E-9 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1207460Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID24975Metabolic constant was measured in male rat (uM)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID59262Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 0.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID73854Action potential duration (APD90) repolarization in guinea pig right papillary muscle was determined at concentration 5 x 10E-9 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID60200Prolongation of ERP(effective refractory index) in mongrel dogs over a 3 hour interval following oral administration (0.3 mg/kg), pacing at a basic cycle length of 250 ms.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID75646Effect of 1 uM of compound, on action potential duration (APD) was determined in isolated guinea-pig papillary muscles at 1 Hz.1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID38583Negative log of concentration (-logC)for delaying functional refractory period 10 ms in animal atrium2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Computer-aided design, synthesis and biological assay of p-methylsulfonamido phenylethylamine analogues.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID56680Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.01 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID71923Dose required to produce 20% increase in effective refractory period in male ferret.2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines.
AID24961Actual in vivo metabolic clearance was measured in human2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID73853Action potential duration (APD90) repolarization in guinea pig right papillary muscle was determined at concentration 5 x 10E-8 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID58463Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1652308Inhibition of human ERG stably expressed in HEK293 cells2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
AID75631Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 100 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
The synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.
AID56529Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID24980Extrapolated in vivo clearance was measured by all pathways. (female rat)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID24962In vitro Intrinsic clearance was measured as Vmax/KM (human)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID22627Maximum rate of depolarization of the upstroke of the action potential1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID161283Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.12003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID56695Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID72554Peak isometric tension during the basic stimulus trains (S1) during control and compound induced tension, expressed as percent control.2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines.
AID56671Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 30 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID60201Prolongation of ERP(effective refractory index) in mongrel dogs over a 3 hour interval following oral administration (0.3 mg/kg), pacing at a basic cycle length of 400 ms.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents.
AID18405Oral bioavailability in dog1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID24970Actual in vivo metabolic clearance was measured in male rat2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207426Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID75642Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 50 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
The synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID24967Extrapolated in vivo clearance was measured by all pathways. (Human)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID24981Extrapolated in vivo clearance was measured by all pathways.(male rat)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID1207156Inhibition of Na channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID59097Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 0.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID59258Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV, at a concentration of 0.3 uM1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID75647Effect of 1 uM of compound, on action potential duration (APD) was determined in isolated guinea-pig papillary muscles at 3 Hz1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID24960Extrapolated in vivo clearance was measured by all pathways.(Dog)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID56239Atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 0.05 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID24976Maximum concentration was measured in female rat2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID290945Inhibition of hERG expressed in HEK293 cells at 25 nM by whole-cell patch clamp method2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID58464Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1207398Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID62966Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56672repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.01 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID56527Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID232326Ratio of APD prolongation was measured as percent change at 3 Hz/1 Hz1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID58465Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID290939Displacement of [3H]dofetilide from hERG expressed in HEK293 cells by SPA2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID59147Compound was evaluated for the intravenous dose required to prolong relative refractory period (RRP) 20 ms above baseline in chloralose anesthetized dogs using a paired pacing protocol1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).
AID24957Maximum concentration was measured in dog2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID38589Tested for its maximal percent change of heart rate in uM2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Computer-aided design, synthesis and biological assay of p-methylsulfonamido phenylethylamine analogues.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID63284Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.01 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID290942Blockade of hERG expressed in HEK293 cells by whole-cell patch clamp method2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID1320524Inhibition of human ERG2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID73845Action potential duration (APD50) repolarization in guinea pig right papillary muscle was determined at concentration 5 x 10E-8 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID59217Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1207554Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID24954In vitro Intrinsic clearance was measured as Vmax/KM.(dog)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID38587Tested for its maximal percent change of delaying functional refractory period in uM2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Computer-aided design, synthesis and biological assay of p-methylsulfonamido phenylethylamine analogues.
AID167261In vitro concentration at which cardiac refractoriness in rabbit is increased by 20 ms1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents.
AID59219Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1207366Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID1207644Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID75079Effective concentration for delaying effective refractory period (ERP) 10 ms in guinea pig2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: design, synthesis, biological assay, and 3D-QSAR analysis.
AID73852Action potential duration (APD90) repolarization in guinea pig right papillary muscle was determined at concentration 10E-6 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID56507Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56506Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID63286Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.03 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID161144Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID18406Oral bioavailability in man1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1739148Inhibition of human ERG expressed in CHO cells by patch clamp method2020European journal of medicinal chemistry, Aug-01, Volume: 199Privileged scaffold-based design to identify a novel drug-like 5-HT
AID24966Extrapolated in vivo clearance was measured by N-demethylation using scalling factors (human)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID60202The orally dosed values in animals (0.3 mg/kg) represent the maximum increase in ERP observed over a 3 hour interval. Pacing was done at basic cycle lengths of 500 ms.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76026Percent change of force of constriction measured in guinea pig at 10e-5 M concentration2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: design, synthesis, biological assay, and 3D-QSAR analysis.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID75205The degree of cardiac depression produced by a concentration of 10 E-4 M was determined in guinea pig1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID56698Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV, at a concentration of 0.3 uM1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID78067Maximum rate of depolarization (MRD) during phase 0 in guinea pig right papillary muscle was determined at concentration 5 x 10E-8 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID38584Tested for its effective concentration for delaying functional refractory period 10 ms in animal atrium2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Computer-aided design, synthesis and biological assay of p-methylsulfonamido phenylethylamine analogues.
AID62936Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID728454Displacement of [3H]astemizole from human ERG K+ channel expressed in HEK293 cells by scintillation spectrophotometric analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
AID56673repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.03 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1207246Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207338Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID24979Extrapolated in vivo clearance was measured by N-demethylation using scalling factors (male rat)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1207520Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID24977Maximum concentration was measured in male rat2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID56683Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.10 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID49075Ventricular fribrillation threshold (VFT) after iv administration to anesthetized, acutely infarcted cats at 0.03 mg/kg1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID1207306Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID232589Ratio of ERPc prolongation was measured as percent change at 3 Hz/1 Hz1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID56237Atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 0.05 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID77985Blockade of the delayed rectifier K+ current (IKr) of guinea pig myocytes1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207185Inhibition of voltage-gated L-type Ca channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID63287Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.03 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID24721Elimination of half life in dog was determined; Range is 4-61990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID78065Maximum rate of depolarization (MRD) during phase 0 in guinea pig right papillary muscle was determined at concentration 10E-6 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID24959Extrapolated in vivo clearance was measured by N-demethylation using scalling factors (Dog)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID73846Action potential duration (APD50) repolarization in guinea pig right papillary muscle was determined at concentration 5 x 10E-9 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID24955Metabolic constant was measured in dog (uM)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID392051Inhibition of human ERG channel in HEK293 cells by voltage-clamp method2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
AID16298Clearance rate in dogs1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID1207492Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID59246Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 0.05 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID24953Actual in vivo metabolic clearance was measured in dog2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID24969Actual in vivo metabolic clearance was measured in female rat2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID75649Effective refractory period of contractile response in isolated guinea-pig papillary muscles at 3 Hz and 1 uM.1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID71928Compound was evaluated for the molar concentration required to prolong effective refractory period (ERP) 25% above baseline in ferret isolated right ventricular papillary muscles using a paired pacing protocol1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).
AID24963Metabolic constant was measured in human (uM)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID290944Permeability from basolateral to apical side of the Caco-2 cell membrane2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID75638Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 250 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
The synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID59266Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 0.05 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID75648Effective refractory period of contractile response in isolated guinea-pig papillary muscles at 1 Hz and 1 uM.1999Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1
Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence.
AID56674repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 0.10 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID24965Maximum concentration was measured in human2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID73844Action potential duration (APD50) repolarization in guinea pig right papillary muscle was determined at concentration 2 x 10E-5 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID1207278Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID290941Ratio of Ki for hERG by SPA to Ki for hERG by fluorescence polarization assay in HEK293 cells2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID59218Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID62967Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59254Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 0.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID270499Inhibition of [3H]dofetilide binding to HERG expressed in HEK293 cells2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
AID62937Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.50 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID59259Effect on trial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 0.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID63289Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.10 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID63288Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.10 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID49032Blockade of Na+ current in frog oocytes expressing human cardiac sodium channel (HH1)1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents.
AID62965Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID38585Tested for its maximal percent change of force of constriction in uM2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Computer-aided design, synthesis and biological assay of p-methylsulfonamido phenylethylamine analogues.
AID59260Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 0.05 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1207738Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID1743139Inhibition of human ERG stably expressed in HEK293 cells by whole-cell manual patch clamp method2020European journal of medicinal chemistry, Nov-15, Volume: 206Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID56528Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 0.25 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID24972In vitro Intrinsic clearance was measured as Vmax/KM (female rat)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID78066Maximum rate of depolarization (MRD) during phase 0 in guinea pig right papillary muscle was determined at concentration 2 x 10E-5 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID74044Concentration required to prolong the effective refractory period (ERP) by 25% in isolated guinea pig left atria1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID24973In vitro Intrinsic clearance was measured as Vmax/KM in male rat2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID62935Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56689Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID290940Binding affinity at hERG expressed in HEK293 cells by fluorescence polarization assay2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID63285Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 0.01 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1207215Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID73843Action potential duration (APD50) repolarization in guinea pig right papillary muscle was determined at concentration 10E-6 M1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID76025Percent change for delaying effective refractory period (ERP) in guinea pig at 10e-5 M concentration2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: design, synthesis, biological assay, and 3D-QSAR analysis.
AID24974Metabolic constant was measured in female rat (uM)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID59248Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 0.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID56505Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 0.05 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID76027Percent change in heart rate measured in guinea pig at 10e-5 M concentration2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: design, synthesis, biological assay, and 3D-QSAR analysis.
AID26256Distribution coefficient at pH 7.41990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID290943Permeability from apical to basolateral side of the Caco-2 cell membrane2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID59252Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 0.05 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID48134Effective refractory period (ERP) after iv administration to anesthetized, acutely infarcted cats at 0.03 mg/kg1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
AID1346732Human Kv10.1 (Voltage-gated potassium channels)2006FEBS letters, Sep-18, Volume: 580, Issue:21
Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (643)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's160 (24.88)18.2507
2000's270 (41.99)29.6817
2010's173 (26.91)24.3611
2020's40 (6.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.87 (24.57)
Research Supply Index6.64 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials65 (9.31%)5.53%
Reviews66 (9.46%)6.00%
Case Studies17 (2.44%)4.05%
Observational2 (0.29%)0.25%
Other548 (78.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]